TWI904076B - 作為用於治療神經退化性疾病的ppargc1a活化劑的2-芳基苯并咪唑 - Google Patents
作為用於治療神經退化性疾病的ppargc1a活化劑的2-芳基苯并咪唑Info
- Publication number
- TWI904076B TWI904076B TW108127925A TW108127925A TWI904076B TW I904076 B TWI904076 B TW I904076B TW 108127925 A TW108127925 A TW 108127925A TW 108127925 A TW108127925 A TW 108127925A TW I904076 B TWI904076 B TW I904076B
- Authority
- TW
- Taiwan
- Prior art keywords
- esi
- alkyl
- benzo
- lcms
- nmr
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D263/57—Aryl or substituted aryl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
- C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
- C07F9/65068—Five-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862714962P | 2018-08-06 | 2018-08-06 | |
| US62/714,962 | 2018-08-06 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202019410A TW202019410A (zh) | 2020-06-01 |
| TWI904076B true TWI904076B (zh) | 2025-11-11 |
Family
ID=69413327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW108127925A TWI904076B (zh) | 2018-08-06 | 2019-08-06 | 作為用於治療神經退化性疾病的ppargc1a活化劑的2-芳基苯并咪唑 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US12195432B2 (https=) |
| EP (1) | EP3833344A4 (https=) |
| JP (2) | JP7422737B2 (https=) |
| KR (1) | KR20210068399A (https=) |
| CN (2) | CN112805000A (https=) |
| AU (1) | AU2019319745B2 (https=) |
| BR (1) | BR112021002165A2 (https=) |
| CA (1) | CA3108773A1 (https=) |
| IL (3) | IL280664B2 (https=) |
| MX (2) | MX2021001456A (https=) |
| SG (1) | SG11202101285YA (https=) |
| TW (1) | TWI904076B (https=) |
| WO (1) | WO2020033359A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12195432B2 (en) | 2018-08-06 | 2025-01-14 | The Board Of Trustees Of The Leland Stanford Junior University | 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases |
| KR20220154772A (ko) * | 2020-03-13 | 2022-11-22 | 주식회사 바이오오케스트라 | Pgc-1a 발현을 사용하는 진단 방법 |
| CN112933232A (zh) * | 2021-02-02 | 2021-06-11 | 袁玉佳 | PGC-1α激活TFEB介导的自噬在制备治疗急性肾损伤的药物中的应用 |
| EP4426295A1 (en) * | 2021-11-02 | 2024-09-11 | Tranquis Therapeutics, Inc. | Selection and treatment of subjects having a circulating myeloid cell inflammatory phenotype |
| US20250262189A1 (en) * | 2022-04-22 | 2025-08-21 | Rdiscovery, LLC | Treatment of diseases associated with reductive stress |
| EP4618982A1 (en) * | 2022-11-18 | 2025-09-24 | GOJO, Satoshi | Uses of zln-005 and related compounds |
| WO2024118936A1 (en) * | 2022-12-02 | 2024-06-06 | Tranquis Therapeutics, Inc. | 2-arylbenzimidazole compounds for the treatment of hemoglobinopathies |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014179303A1 (en) * | 2013-04-29 | 2014-11-06 | The General Hospital Corporation | Amyloid precursor protein mrna blockers for treating down syndrome and alzheimer's disease |
| WO2016061190A1 (en) * | 2014-10-14 | 2016-04-21 | The Board Of Trustees Of The Leland Stanford Junior University | Method for treating neurodegenerative diseases |
| WO2017106050A1 (en) * | 2015-12-15 | 2017-06-22 | The Board Of Trustees Of The Leland Stanford Junior University | Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE614236A (https=) | 1961-03-01 | |||
| FR1569337A (https=) * | 1968-06-18 | 1969-05-30 | ||
| US4038396A (en) * | 1975-02-24 | 1977-07-26 | Merck & Co., Inc. | Anti-inflammatory oxazole[4,5-b]pyridines |
| GB1584296A (en) | 1976-12-07 | 1981-02-11 | Kanebo Ltd | 2-substituted benzimidazole compounds |
| NZ234564A (en) | 1986-11-21 | 1991-04-26 | Haessle Ab | 1-substituted benzimidazoles and pharmaceutical compositions |
| DE3830060A1 (de) | 1988-09-03 | 1990-03-15 | Boehringer Mannheim Gmbh | 2-phenylbenzimidazole - verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel |
| US5552426A (en) | 1994-04-29 | 1996-09-03 | Eli Lilly And Company | Methods for treating a physiological disorder associated with β-amyloid peptide |
| JPH09169729A (ja) * | 1995-12-19 | 1997-06-30 | Green Cross Corp:The | 非ペプチド型インターロイキン８拮抗剤 |
| CA2258728C (en) * | 1996-06-19 | 2011-09-27 | Rhone Poulenc Rorer Limited | Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase |
| JP2000143635A (ja) * | 1998-06-10 | 2000-05-26 | Takeda Chem Ind Ltd | 血管新生阻害剤 |
| JP2000095767A (ja) * | 1998-09-28 | 2000-04-04 | Takeda Chem Ind Ltd | 性腺刺激ホルモン放出ホルモン拮抗剤 |
| DE59911249D1 (de) | 1998-11-03 | 2005-01-13 | Abbott Gmbh & Co Kg | Substituierte 2-phenylbenzimidazole, deren herstellung und anwendung |
| US20070004713A1 (en) * | 2000-12-07 | 2007-01-04 | Bernard Barlaam | Therapeutic benimidazole compounds |
| DE10134775A1 (de) * | 2001-07-06 | 2003-01-30 | Schering Ag | 1-Alkyl-2.aryl-benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate |
| SE0301371D0 (sv) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | New Compounds |
| KR20070032700A (ko) | 2004-05-20 | 2007-03-22 | 폴드알엑스 파마슈티칼스, 인크. | 트랜스티레틴을 안정화하고 트랜스티레틴 미스폴딩을억제하기 위한, ２-((헤테로)아릴)-벤즈옥사졸 화합물 및유도체, 그리고 조성물 및 방법 |
| RU2007101509A (ru) | 2004-06-17 | 2008-07-27 | Уайт (Us) | Способ получения антагонистов рецепторов гормона, высвобождающего гонадотропин |
| WO2006122546A1 (de) * | 2005-05-18 | 2006-11-23 | Forschungsverbund Berlin E.V. | Nicht-peptidische inhibitoren der akap-pka-wechselwirkung |
| CA2616512A1 (en) | 2005-07-28 | 2007-02-08 | Intervet International B.V. | Novel benzimidazole (thio) carbamates with antiparasitic activity and the synthesis thereof |
| EP1910385B1 (en) | 2005-08-04 | 2013-07-24 | Sirtris Pharmaceuticals, Inc. | Benzothiazoles and thiazolopyridines as sirtuin modulators |
| US7915299B2 (en) | 2006-11-15 | 2011-03-29 | High Point Pharmaceuticals, Llc | 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes |
| GB0807103D0 (en) | 2008-04-18 | 2008-05-21 | Univ Bradford The | Compounds |
| JP2012529449A (ja) * | 2009-06-11 | 2012-11-22 | シエナ ビオテク ソシエタ ペル アチオニ | ヘッジホッグ経路アンタゴニストおよびそれらの治療的応用 |
| WO2011047129A1 (en) * | 2009-10-15 | 2011-04-21 | Southern Research Institute | Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such |
| BR112012010738A2 (pt) * | 2009-11-06 | 2019-09-24 | Univ Vanderbilt | ''aril e heteroaril sulfonas como potenciadores alostéricos de mglur4,composições e métodos de tratamento de disfunção neurológica'' |
| GB201009656D0 (en) | 2010-06-09 | 2010-07-21 | Univ St Andrews | Carboxylation catalysts |
| JP5083393B2 (ja) | 2010-09-16 | 2012-11-28 | カシオ計算機株式会社 | 画像表示装置及びプログラム |
| EP2651405A2 (en) * | 2010-12-14 | 2013-10-23 | Electrophoretics Limited | Casein kinase 1 (ck1 ) inhibitors |
| US8865754B2 (en) * | 2011-03-03 | 2014-10-21 | Proteotech Inc. | Compounds for the treatment of neurodegenerative diseases |
| AU2013250726B2 (en) | 2012-04-20 | 2017-01-05 | Advinus Therapeutics Limited | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof |
| EA201590482A1 (ru) * | 2012-09-05 | 2015-07-30 | Байер Кропсайенс Аг | Применение замещенных 2-амидобензимидазолов, 2-амидобензоксазолов и 2-амидобензотиазолов или их солей в качестве биологически активных веществ против абиотического стресса растений |
| KR101435496B1 (ko) | 2012-10-22 | 2014-08-28 | 한국과학기술연구원 | 미토콘드리아 기능 조절제로서의 벤즈이미다졸 유도체 |
| GB201302927D0 (en) * | 2013-02-20 | 2013-04-03 | Cancer Therapeutics Crc Pty Ltd | Compounds |
| CN103113307B (zh) * | 2013-02-27 | 2015-08-05 | 南京大学 | 苯并咪唑类化合物及其应用 |
| CN104873500A (zh) | 2015-04-29 | 2015-09-02 | 中国人民解放军第四军医大学 | 化合物zln005的用途 |
| CA2984971A1 (en) * | 2015-05-11 | 2016-11-17 | Kancera Ab | Benzimidazole derivates useful as inhibitors of mammalian histone deacetylase activity |
| RU2747431C2 (ru) * | 2015-12-22 | 2021-05-05 | Кансера Аб | Бициклические гидроксамовые кислоты, полезные в качестве ингибиторов активности деацетилазы гистонов млекопитающих |
| JP2018083799A (ja) | 2016-11-15 | 2018-05-31 | バイオエレクトロン テクノロジー コーポレイション | ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩 |
| US12195432B2 (en) | 2018-08-06 | 2025-01-14 | The Board Of Trustees Of The Leland Stanford Junior University | 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases |
-
2019
- 2019-08-06 US US17/266,433 patent/US12195432B2/en active Active
- 2019-08-06 JP JP2021506624A patent/JP7422737B2/ja active Active
- 2019-08-06 MX MX2021001456A patent/MX2021001456A/es unknown
- 2019-08-06 WO PCT/US2019/045229 patent/WO2020033359A1/en not_active Ceased
- 2019-08-06 IL IL280664A patent/IL280664B2/en unknown
- 2019-08-06 CN CN201980065941.4A patent/CN112805000A/zh active Pending
- 2019-08-06 EP EP19845943.0A patent/EP3833344A4/en active Pending
- 2019-08-06 IL IL307972A patent/IL307972A/en unknown
- 2019-08-06 KR KR1020217006736A patent/KR20210068399A/ko not_active Ceased
- 2019-08-06 CN CN202411199938.0A patent/CN119033775A/zh active Pending
- 2019-08-06 SG SG11202101285YA patent/SG11202101285YA/en unknown
- 2019-08-06 BR BR112021002165-5A patent/BR112021002165A2/pt not_active Application Discontinuation
- 2019-08-06 TW TW108127925A patent/TWI904076B/zh active
- 2019-08-06 CA CA3108773A patent/CA3108773A1/en active Pending
- 2019-08-06 AU AU2019319745A patent/AU2019319745B2/en active Active
- 2019-08-06 IL IL298535A patent/IL298535B2/en unknown
-
2020
- 2020-05-29 US US16/888,040 patent/US10851066B2/en active Active
- 2020-10-13 US US17/068,985 patent/US11111217B2/en active Active
-
2021
- 2021-02-04 MX MX2023012694A patent/MX2023012694A/es unknown
-
2024
- 2024-01-16 JP JP2024004449A patent/JP2024056694A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014179303A1 (en) * | 2013-04-29 | 2014-11-06 | The General Hospital Corporation | Amyloid precursor protein mrna blockers for treating down syndrome and alzheimer's disease |
| WO2016061190A1 (en) * | 2014-10-14 | 2016-04-21 | The Board Of Trustees Of The Leland Stanford Junior University | Method for treating neurodegenerative diseases |
| WO2017106050A1 (en) * | 2015-12-15 | 2017-06-22 | The Board Of Trustees Of The Leland Stanford Junior University | Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021002165A2 (pt) | 2021-05-04 |
| AU2019319745A1 (en) | 2021-03-25 |
| TW202019410A (zh) | 2020-06-01 |
| US12195432B2 (en) | 2025-01-14 |
| IL280664A (en) | 2021-03-25 |
| US20200299244A1 (en) | 2020-09-24 |
| AU2019319745B2 (en) | 2025-06-26 |
| MX2021001456A (es) | 2021-05-27 |
| IL280664B (en) | 2022-12-01 |
| US20210061769A1 (en) | 2021-03-04 |
| IL307972A (en) | 2023-12-01 |
| IL298535A (en) | 2023-01-01 |
| WO2020033359A1 (en) | 2020-02-13 |
| CN112805000A (zh) | 2021-05-14 |
| SG11202101285YA (en) | 2021-03-30 |
| US11111217B2 (en) | 2021-09-07 |
| US20210300877A1 (en) | 2021-09-30 |
| CN119033775A (zh) | 2024-11-29 |
| EP3833344A4 (en) | 2022-07-06 |
| IL280664B2 (en) | 2023-04-01 |
| US10851066B2 (en) | 2020-12-01 |
| MX2023012694A (es) | 2023-11-21 |
| JP2021534099A (ja) | 2021-12-09 |
| CA3108773A1 (en) | 2020-02-13 |
| JP7422737B2 (ja) | 2024-01-26 |
| EP3833344A1 (en) | 2021-06-16 |
| IL298535B2 (en) | 2024-03-01 |
| JP2024056694A (ja) | 2024-04-23 |
| KR20210068399A (ko) | 2021-06-09 |
| IL298535B1 (en) | 2023-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI904076B (zh) | 作為用於治療神經退化性疾病的ppargc1a活化劑的2-芳基苯并咪唑 | |
| JP4054845B2 (ja) | 神経変性障害の治療のためのイミダゾール化合物 | |
| TW202016073A (zh) | B型肝炎蛋白殼組裝調節劑 | |
| IL255449B2 (en) | Inhibitors of histone deacetylase and their compositions and methods of use | |
| JP2010523725A (ja) | 皮膚疾患処置用ホスホジエステラーゼ阻害剤としてのトリアゾロピリジン | |
| UA109802C2 (xx) | Похідні біцикло$3.2.1]октиламіду та їх застосування | |
| JP7835446B2 (ja) | 新規な複素環式化合物 | |
| EP2262808A2 (en) | Chemokine receptor modulators | |
| EP3986879B1 (en) | Fused 1,2-thiazoles and 1,2-thiazines which act as nlrp3 modulators | |
| WO2009085256A1 (en) | Anti-hiv compounds | |
| MX2013008629A (es) | Inhibidores de histona desacetilasa y composiciones y metodos para su uso. | |
| AU2018212438A1 (en) | Bicyclic bis-heteroaryl derivatives as modulators of protein aggregation | |
| CN109843879B (zh) | 作为dyrk1抑制剂的苯并噻唑衍生物 | |
| JP7041141B2 (ja) | 置換された二環式ヘテロアリール系ニコチン性アセチルコリン受容体アロステリック調節剤 | |
| CA2758961A1 (en) | Substituted isoquinoline derivatives, pharmaceutical compositions, and methods of use as .beta.-secretase inhibitors | |
| CN114478537B (zh) | 环酰胺并环化合物及其医药用途 | |
| TW202229277A (zh) | 用於治療隱孢子蟲病之化合物及組成物 | |
| CA3204133A1 (en) | Indole derivatives as kinase inhibitors | |
| JP2024520758A (ja) | Ｔｔｂｋ１の阻害剤 | |
| HK40003735A (en) | Bifunctional molecules for degradation of egfr and methods of use |